The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. ” said José Camacho, director of HPC & Quantum computing of Atos in Iberia. This 5-Star Analyst Thinks Its Possible, Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossas Second COVID-19 Therapeutic Development Program, Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture, Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls. 5,231 Atos reviews. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues, Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force, Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter, Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019, Today's Research Reports on Trending Tickers: BioTelemetry and Atossa Genetics, 4 Healthcare Stocks Looking To Set January Highs, Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen. He previously served as Syntel's CEO and President from November 3, 2016 [20] until the October, 2018 merger with Atos. The first Syntel offshore development centers were established in Mumbai in 1992, with centers opening in Chennai soon after. Jeff Bezos will step down as Amazon CEO and become the company's executive chairman later this year. The Company's U.S.-based development centers are located in Phoenix, Arizona, Nashville, Tennessee, and Memphis, Tennessee. He previously served as Syntel's Chief Operating Officer January 2012 until November 2016, and as President of the Banking and Financial Services Business Unit from 2005 until 2012. https://timesofindia.indiatimes.com/business/international-business/atos-completes-acquisition-of-syntel/articleshow/66145382.cms#:~:text=Based%20on%20the%20terms%20of,wholly%20owned%20subsidiary%20of%20Atos.&text=Post%20the%20acquisition%2C%20Syntel%20shares,be%20delisted%20from%20the%20NASDAQ, "Syntel Names Rakesh Khanna CEO and President", "Syntel enters definitive agreement to be acquired by Atos S.E. Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing, Atossa Genetics Announces FDA Approval of Oral Endoxifen for Expanded Access as Post-Mastectomy Treatment for a U.S. Real-time quotes, advanced visualizations, backtesting, and much more. The transition, slated for the third quarter, will make Amazon Web Services' (AWS) founder Andy Jassy Amazon's next chief executive officer. Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019, Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update, Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference, Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology, Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia, Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen, Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference, Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet, Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update, Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk, Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests, Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated, A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019, Atossa Genetics Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density, Some Atossa Genetics (NASDAQ:ATOS) Shareholders Have Copped A 99% Share Price Wipe Out, Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019, Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update, Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit, Reducing This Amino Acid May Aid In Fight Against Breast Cancer, Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019, Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update, Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density, Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference, Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day "Transforming Breast Cancer Treatment", Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020. In 1992, with new development centers in India, Syntel began software outsourcing services with an onsite-offshore model, which connected software developers in India to project managers at client locations via an international telecommunications network. Atos Syntel is a subsidiary of Atos and a multinational provider of integrated technology and business services.The company is led by Rakesh Khanna. Atos had last month proposed to acquire DXC, an IT services firm formed by the merger of CSC and services business of HP Enterprise, for $10 billion including debt. “Atos Scaler is committed to unleash the value of collaboration, by facilitating open innovation and giving birth to very concrete industrial applications, with accelerated time-to-market.” Elie Girard, Atos CEO Breast Cancer Patient, Atossa Genetics Announces Receipt of $10 Million. ", "Syntel to expand in Chennai; acquires 27.52 acre land -Software-News-Indiatimes", "Syntel Promotes Keshav Murugesh to Chief Executive Officer", "Syntel names Prashant Ranade new CEO - CIOL", https://globenewswire.com/news-release/2012/01/03/464536/241752/en/Syntel-Promotes-Rakesh-Khanna-to-Chief-Operating-Officer.html, "Syntel CEO Steps Down, COO Named As Interim Replacement", https://atos.net/en/2018/press-release_2018_10_09/atos-digital-leadership-strengthened-completion-acquisition-us-based-syntel, https://www.thehindubusinessline.com/info-tech/software-firm-atos-opens-new-global-delivery-centre-in-tirunelveli/article26980151.ece, https://en.wikipedia.org/w/index.php?title=Atos_Syntel&oldid=1003054481, International information technology consulting firms, American subsidiaries of foreign companies, Wikipedia articles containing buzzwords from July 2019, Articles with unsourced statements from July 2019, Creative Commons Attribution-ShareAlike License, This page was last edited on 27 January 2021, at 05:55. Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021 GlobeNewswire +59.36% Jan-08-21 06:02AM The HDF-Atos partnership offers the first unique and sustainable infrastructure for this huge market.” says Damien Havard, CEO at HDF. Announcement is next strategic phase in combining innovative cloud contact center and video meeting solutions for the new hybrid work paradigm CEO move follows recent hires of Ashish Seth as general manager of contact center solutions from NICE inContact and other sales and marketing executives from Talkdesk and Vonage Lifesize, Inc., a leader and global provider of cloud contact … Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19, Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen, Registration Is Now Open for Atossa Therapeutics Tribe Public Webinar Presentation and Q&A Event on July 30, 2020, Atossa Stock at $8 a Share? View the Hyundai Atos Online & Test Drive a New Hyundai Atos Near You. LD Micro Announces Preliminary List of Presenters for the LD-500. Their average twelve-month price target is $7.50, … Originally founded in 1980 as Syntel International by Bharat Desai and Neerja Sethi in Troy, Michigan Syntel began by providing software staffing services to local corporations like General Motors (US),[7] and some major governmental units, earning $30,000 in its first year. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc. Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women. Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans? In 2011 Atos introduced a Zero Email initiative, banning email as a form of internal communications, except for use with customers and prospects. In 2012 Atos announced the creation of a new company called Canopy. Atos Syntel is a subsidiary [4] of Atos and a multinational provider of integrated technology and business services. In 2005, Syntel opened a large technology campus in Pune. [citation needed]. Atos Syntel operates facilities in the United States, United Kingdom, Germany and offshore software development centers in Mumbai, Chennai, Tirunelveli, Hyderabad, Gurgaon and Pune, India, as well as Manila, Philippines. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington. Breast Cancer Patient, "On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter, Atossa Genetics Reports Results From Expanded Access Program for a U.S. Join thousands of traders who make more informed decisions with our premium features. [8], Atos Syntel provides IT services such as traditional application development and maintenance, data warehousing and business intelligence, as well as digital services like social media, mobile, cloud, analytics, IoT and AI and automation-powered solutions. Rakesh Khanna is the CEO of Atos Syntel and a member of the Atos Executive Committee. [19] In May, 2010, Syntel also opened the first phase of a 27-acre (110,000 m2) technology campus in Chennai, India. Atos has been on an acquisition spree over the past few years. In 2018 it acquired Syntel to expand its services and enter new markets. [5] Atos Syntel was created by the acquisition of Syntel, Inc. by Atos S.E.,[6] which was announced on July 22, 2018 and completed on October 9, 2018. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. Please. 2 Wall Street analysts have issued ratings and price targets for Atossa Therapeutics in the last 12 months. A free inside look at company reviews and salaries posted anonymously by employees. What Type Of Shareholder Owns Atossa Genetics Inc.s (NASDAQ:ATOS)? Your browser is no longer supported. Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201, Potential Life Saving COVID-19 Survival Manual Removed from Amazon Kindle Store Three Days before Official Launch, SARS-CoV-2 was spreading in the United States in late December 2019 and may have killed over 440 patients in California and 980 nationwide by mid-January 2020, Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study, Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture, Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs, Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment, Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs, Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study, Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says Buy, Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study, COVID-19 Cease Fire for the United States on April 23, 2020 and successful Opening Up America Again initiative predicted, Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program, Atossa Therapeutics Announces Clinical Progress, New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients, Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update, Atossa Therapeutics Announces Upcoming Meeting with FDA, Atossa Therapeutics, Inc. [8], Syntel's early growth prompted their leadership to explore additional service offerings to augment the core IT staffing business.[8]. Find the latest Atossa Therapeutics, Inc. (ATOS) stock quote, history, news and other vital information to help you with your stock trading and investing. Integral to its operating model are the use of offshore centers to deliver IT and KPO services. DXC earlier confirmed the proposal to ET. The company is led by Rakesh Khanna. Atos Syntel was created by the acquisition of Syntel, Inc. by Atos S.E., which was announced on July 22, 2018 and completed on October 9, 2018. This new success strengthens our commitment as a European leader in the meteorology sector. Is Atossa Genetics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans? In 1989, Syntel began providing development and maintenance services to its clients. View Now! The CEO is Philippe Llorens. Experience Hyundai Vehicle Quality, Service and 7 Year Car Warranty. [buzzword], The company markets its services to enterprises in the banking and financial services, insurance, healthcare and life sciences, retail, logistics and telecom, and manufacturing sectors. Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Atossas Nasal Spray Candidate Could Yet Join the Fight Against COVID-19, Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19, Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021, Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen, Atossa Therapeutics Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early, Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants, New Study By Dr. Steven Quay Concludes that SARS-CoV-2 Came from a Laboratory, Registration Is Now Open For Tribe Publics Webinar Event The Important Role of COVID Therapeutics in a Post-Vaccine World Featuring Atossa Therapeutics CEO & CFO On February 2, 2021, Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021, COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay, Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market, Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market, Here's Why We're A Bit Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation, Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering, Foxx Life Sciences Announces Opening of New Asia Headquarters in India, Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update, Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19, New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic, Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID, Registration Is Now Open For Atossa Therapeutics Tribe Public Webinar Presentation and Q&A Event On October 13, 2020, Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, "Stay Safe: A Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First Family, Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020, Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID, Physician-Scientist Dr. Steven Quay's "Stay Safe: A Physician's Guide to Survive Coronavirus" Reaches #1 on Five Amazon Bestsellers Lists, Physician-Scientist Dr. Steven Quay Shares Back-to-School Tips To Stay Safe and Survive Coronavirus, Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19, LD Micro: 360 Companies - Set to Present this Week, Penny Stocks to Buy Using Technical Analysis for September 2020, Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020, Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19, Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update. Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.